04Jan 2023
Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer

Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer

The study investigated the influence of ICB on SARS-CoV-2-spike protein (SP) antibody titers and T-cell responses in cancer patients previously vaccinated against COVID-19. The study interprets these results as evidence that ICB immunotherapy does not significantly enhance SARS-CoV-2-specific antibody titers or T-cell responses. Although the study lacks corresponding IRAE rates, the results provide humoral and cellular immunological data that support recent reports documenting the clinical safety and efficacy of COVID-19 vaccination in patients receiving ICB.

  • #family health

Like

Save

Share